Does IRBESARTAN Cause Mobility decreased? 24 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 24 reports of Mobility decreased have been filed in association with IRBESARTAN (Irbesartan). This represents 0.2% of all adverse event reports for IRBESARTAN.
24
Reports of Mobility decreased with IRBESARTAN
0.2%
of all IRBESARTAN reports
0
Deaths
12
Hospitalizations
How Dangerous Is Mobility decreased From IRBESARTAN?
Of the 24 reports, 12 (50.0%) required hospitalization.
Is Mobility decreased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for IRBESARTAN. However, 24 reports have been filed with the FAERS database.
What Other Side Effects Does IRBESARTAN Cause?
Acute kidney injury (1,361)
Fall (795)
Hypotension (686)
Nausea (533)
Drug ineffective (532)
Malaise (488)
Hyponatraemia (485)
Fatigue (483)
Blood pressure increased (477)
Hyperkalaemia (454)
What Other Drugs Cause Mobility decreased?
ADALIMUMAB (8,829)
ETANERCEPT (8,321)
METHOTREXATE (5,936)
ABATACEPT (4,519)
TOCILIZUMAB (4,403)
LEFLUNOMIDE (4,354)
HYDROXYCHLOROQUINE (4,105)
RITUXIMAB (4,067)
INFLIXIMAB (3,784)
TOFACITINIB (3,734)
Which IRBESARTAN Alternatives Have Lower Mobility decreased Risk?
IRBESARTAN vs IRINOTECAN
IRBESARTAN vs IRON
IRBESARTAN vs IRON DEXTRAN
IRBESARTAN vs IRON ISOMALTOSIDE 1000
IRBESARTAN vs IRON POLYMALTOSE